Anne Schuind

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +16

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i>^®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

Mark H. Einstein, Mira Baron, Myron J. Levin et al. · Human Vaccines · 2009 · 401 citations · Full text

Medicine, Immunology, Oncology +15

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 254 citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson et al. · Human Vaccines · 2011 · 194 citations · Full text

Veterinary Medicine, Immunology, Oncology +13